AOD-9604 vs MOTS-c: Research Literature Comparison
Where AOD-9604 and MOTS-c overlap in the literature, and where they do not, is the substance of this reference.
Side-by-side research profile
| Parameter | AOD-9604 | MOTS-c |
|---|---|---|
| PubMed indexed records | 16 | 255 |
| Registered studies (ClinicalTrials.gov) | 0 | 9 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
AOD-9604 in the indexed record
Searching AOD-9604 against the PubMed index returns 16 records, a limited evidence base with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
MOTS-c in the indexed record
MOTS-c returns 255 indexed records on PubMed, a moderate record, alongside 9 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Adv Sci (Weinh), Cardiovasc Drugs Ther, Front Endocrinol (Lausanne), spanning 2022–2025.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Adv Sci (Weinh), 2024. PMID: 39321430
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox Biol, 2025. PMID: 40403491
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? — Cardiovasc Drugs Ther, 2025. PMID: 40172798
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023. PMID: 36761202
How the literature differs
The indexed record is not symmetrical between these two compounds. MOTS-c carries 239 more indexed records than AOD-9604, which means published methodology, characterisation data and replication attempts are more readily located for MOTS-c. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 9) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
AOD-9604 and MOTS-c sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to MOTS-c without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Selecting between them for a study design
AOD-9604 and MOTS-c are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (MOTS-c) generally offers more methodological precedent.
Frequently asked questions
Which of AOD-9604 or MOTS-c has more published research?
MOTS-c, with 255 indexed PubMed records against 16.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are AOD-9604 and MOTS-c the same compound?
No. They are structurally distinct research compounds with separate literature records — 16 indexed records for AOD-9604 and 255 for MOTS-c.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- AOD-9604 — product and lot documentation
- MOTS-c — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.